Dolby Laboratories, Inc. Form 4 Filings

Dolby Laboratories, Inc. (symbol: DLB) is the issuer of record for a Form 4 filing submitted to the SEC. Couling John D reported acquisition or exercise transactions in this Form 4 filing.

Dolby Laboratories, Inc. executive John D. Couling, SVP, Entertainment, received an equity compensation grant of 48,076 restricted stock units (RSUs) of Class A Common Stock on September 15, 2026 under the company’s 2020 Stock Plan. All RSUs vest on September 15, 2028, subject to his continued service, with each unit delivering one share upon vesting. Following this award, he holds 166,803 Class A shares in total, including 103,190 shares underlying unvested RSUs that remain subject to forfeiture. No Rule 10b5-1 trading plan is reported.

Dolby Laboratories, Inc. (DLB) reported that executive vice president, general counsel and secretary Mark Andrew Sherman received a grant of 48,076 restricted stock units of Class A common stock on September 15, 2026 under the company’s 2020 Stock Plan. These units vest 100% on September 15, 2028, contingent on his continued service, with each unit representing a right to receive one Class A share upon vesting. Following this award, Sherman holds 119,024 Class A shares directly, including 101,712 shares underlying unvested restricted stock units and 385 shares acquired through the Employee Stock Purchase Plan. No Rule 10b5-1 trading plan is reported.

Dolby Laboratories, Inc. (DLB) reported that John D. Couling, SVP, Entertainment, exercised stock options and sold shares on September 1, 2026 under an affirmed Rule 10b5-1 trading plan. He exercised options for 7,667 shares of Class A Common Stock at an exercise price of $45.50 per share and received 7,667 shares. On the same date, he sold 7,667 shares of Class A Common Stock at a weighted average price of $61.045 per share in multiple transactions priced between $60.65 and $61.25. The exercised options were part of an option originally granted for 46,000 shares, and his holdings after the transactions include 55,114 shares underlying restricted stock units that remain subject to forfeiture until vesting.

Dolby Laboratories, Inc. (DLB) reported insider transactions involving long‑time significant holder Dagmar Dolby and related trusts on August 28, 2026. The Dagmar Dolby Trust converted 300,000 shares of Class B Common Stock into 300,000 shares of Class A Common Stock at no cost and gifted all such Class A shares to an unaffiliated charitable organization, a transaction the footnotes state is exempt from Section 16(b) under Rule 16b-5.

On the same date, the Dagmar Dolby Trust restructured ownership by contributing a total of 2,000,000 Class B shares (convertible 1‑for‑1 into Class A) for no value, with 1,000,000 shares moved to the Dagmar Dolby 2026 Trust AA‑2 and 1,000,000 shares to the Dagmar Dolby 2026 Trust BB, described as tax and estate planning transfers. All reported holdings are indirect, largely through trusts and LLCs, and the reporting persons disclaim beneficial ownership beyond their pecuniary interests.

Dolby Laboratories, Inc. (DLB) reported that Ryan Nicholson, VP, CAO and Corporate Controller, sold 1,183 shares of Class A Common Stock on 2026-08-25 in an open market or private transaction at a price of $65.2773 per share. Following this sale, Nicholson held a reported total of 34,453 shares of Class A Common Stock, which the company notes includes 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories, Inc. (DLB) executive Shriram Revankar, SVP, Advanced Technology Group, reported selling 3,000 shares of Class A common stock on 2026-08-14 at $62.71 per share in an open-market or private transaction. The transaction was made pursuant to a Rule 10b5-1 trading plan. After this sale, he holds 73,274 shares directly, including 46,938 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories, Inc. officer Ryan Nicholson, VP, CAO and Corporate Controller, sold 1,348 shares of Class A common stock on 2026-08-10 at $62.04 per share in an open market or private transaction. Following the sale, he reported 35,636 shares held directly, including 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories, Inc. executive Ryan Nicholson, VP, CAO and Corporate Controller, sold 357 shares of Class A Common Stock on August 4, 2026 at $60.63 per share. After this sale, he holds 36,984 shares, including 19,303 underlying restricted stock units subject to vesting and 385 shares acquired through the Employee Stock Purchase Plan.

Dolby Laboratories SVP, Entertainment John D. Couling exercised employee stock options for 7667 shares of Class A common stock at an exercise price of $45.5000 and, on the same day, sold 783 shares at a weighted average price of $59.0343 and 6884 shares at $60.1075 pursuant to a Rule 10b5-1 trading plan. He continues to hold options for 15334 shares, and his holdings include 55,114 shares underlying restricted stock units that remain subject to vesting conditions.

Dolby Laboratories, Inc. senior vice president of Entertainment John D. Couling reported an option exercise and related share sale. On July 1, 2026, he exercised employee stock options to acquire 7,667 shares of Class A common stock at $45.50 per share and sold 7,667 shares in open-market transactions at a weighted average price of $53.2013 per share. After these transactions, he directly holds 118,727 shares of Class A common stock, which the filing notes includes 55,114 shares underlying restricted stock units that remain subject to vesting. The derivative holdings section shows 23,001 employee stock options remaining outstanding following the exercise.

Dolby Laboratories SVP, Entertainment John D. Couling exercised stock options for 7,666 shares of Class A common stock at $45.50 per share and sold 7,666 shares in open‑market transactions around the mid‑$50s.

The sales, effected at weighted average prices of $56.16 and $55.5868 per share, were made under a Rule 10b5‑1 trading plan adopted on February 3, 2026. After these transactions he directly holds 118,727 shares, including 55,114 shares underlying restricted stock units subject to vesting and 374 shares from the Employee Stock Purchase Plan.

Dolby Laboratories, Inc. SVP and Chief Marketing Officer Todd Pendleton sold Class A Common Stock in an open-market transaction. On May 22, 2026, he sold 11,876 shares at a weighted average price of $54.5518 per share, in multiple trades priced between $54.315 and $55.08.

Following the sale, Pendleton holds 41,480 shares of Class A common stock directly. According to the footnotes, this post-transaction amount includes shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories SVP Shriram Revankar reported two Class A Common Stock transactions. On May 15, 2026, he sold 3,000 shares in an open-market transaction at $54.90 per share, executed under a Rule 10b5-1 trading plan adopted on August 22, 2025.

On May 18, 2026, 4,329 shares were withheld by Dolby to cover tax obligations from restricted stock unit vesting, a disposition exempt under Rule 16b-3 rather than a market sale. Following these transactions, he directly holds 76,274 shares, including 46,938 shares underlying restricted stock units that remain subject to vesting and 385 shares acquired through the Employee Stock Purchase Plan.

Dolby Laboratories SVP & Chief Financial Officer Robert J. Park reported open-market sales of a total of 4,895 shares of Class A common stock on May 12, 2026. The trades included 391 shares at $57.35 and 4,504 shares at $56.6165, within a price range of $56.335 to $57.13. After these transactions, his holdings include 48,874 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories SVP, Entertainment John D. Couling reported multiple stock transactions in Dolby Laboratories, Inc. Class A Common Stock. On May 4–5, 2026, he sold a total of 12,354 shares in open-market transactions at weighted average prices around $57–$58 per share.

On the same date, he also exercised employee stock options covering 7,666 shares at an exercise price of $45.50 per share. A footnote states that shares held following these transactions include 55,114 shares underlying restricted stock units that remain subject to forfeiture until they vest.

The sales were executed in multiple trades within disclosed price ranges and were carried out under a Rule 10b5-1 trading plan adopted on February 3, 2026, indicating they were pre-scheduled rather than discretionary market-timing decisions.

Dolby Laboratories director Emily Rollins reported an open-market sale of 1,000 shares of Class A common stock at $60.08 per share on April 1, 2026. After this transaction, she directly holds 12,541 shares of Class A common stock.

Her post-transaction holdings include 3,908 shares underlying restricted stock units that remain subject to forfeiture until they vest, meaning part of her reported position is tied to future service or performance conditions rather than fully vested stock.

Dolby Laboratories, Inc. insider reporting centers on indirect holdings controlled through family trusts. On February 25, 2026, the Dagmar Dolby Trust contributed 1,000,000 shares of Class B Common Stock to a newly formed grantor retained annuity trust, described as a transfer for no value for tax and estate planning purposes. On the same date, the Dagmar Dolby Trust also converted 10,000 shares of Class B into 10,000 shares of Class A and gifted all those Class A shares to an unaffiliated charitable organization at no cost. Voting and investment power over various Class B positions is allocated among special trustees and LLC managers, and Dagmar Dolby disclaims beneficial ownership beyond her pecuniary interest.

Dolby Laboratories, Inc. executive Shriram Revankar reported an open-market sale of company stock. On 02/17/2026, he sold 3,000 shares of Class A common stock at $66.14 per share. After this transaction, he beneficially owned 83,218 Class A shares, including 59,172 shares underlying restricted stock units that may be forfeited if they do not vest.

Dolby Laboratories executive Ryan Nicholson, VP, CAO and Corporate Controller, reported an option exercise and share sale. On 02/13/2026 he exercised an employee stock option for 2,667 shares of Class A common stock at an exercise price of $45.50 per share, converting the derivative into common stock.

That same day, he sold 2,667 Class A shares in open-market transactions at a weighted average price of $66.3752 per share, in trades ranging from $66.37 to $66.39. After these transactions, he directly owns 36,956 Class A shares, including 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories, Inc. insider trust reports share conversion and charitable gift. On February 11, 2026, the Dagmar Dolby Trust converted 380,000 shares of Class B Common Stock into 380,000 shares of Class A Common Stock at no cost to the holder. Immediately afterward, the trust made a bona fide gift of all 380,000 Class A shares to an unaffiliated charitable organization, leaving that trust with no Class A shares from this transaction. The filing also lists large remaining indirect holdings of convertible Class B Common Stock across several Dolby family trusts and LLCs, all of which are convertible into Class A on a 1‑for‑1 basis.

Dolby Laboratories President and CEO Kevin J. Yeaman, who is also a director, reported an internal transfer of employee stock options rather than a market trade. On February 5, 2026, an option covering 145,252 shares of Dolby Class A common stock with a $66.62 exercise price was moved from his direct ownership to the Kevin and Rachel Yeaman Family Trust, a revocable trust, for no consideration.

The filing notes this change was made for estate planning purposes and is exempt from Section 16(b) under Rule 16b‑5. The option was originally granted for 145,252 shares, with one-quarter vesting on the first anniversary of December 15, 2025 and the remaining shares vesting in equal monthly installments over the subsequent 36 months, and it expires on December 15, 2035.

Dolby Laboratories director Simon Segars received an equity award of 3,908 restricted stock units of Class A common stock on 02/03/2026 under the company’s 2020 Stock Plan at a grant price of $0 per share. Each unit represents one share of Class A common stock upon vesting.

The units vest on the earlier of the first anniversary of the grant date or the day immediately before Dolby’s 2027 annual shareholders meeting, as long as Segars continues serving on the board. After this grant, he beneficially owns 47,150 Class A shares, including 3,908 unvested RSUs that remain subject to forfeiture until they vest.

Dolby Laboratories director and 10% owner David Dolby received an equity award of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026. The RSUs were granted at a price of $0 per unit under the company’s 2020 Stock Plan.

Each RSU represents a contingent right to receive one share of Class A common stock that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholders’ meeting, as long as he continues to serve on the board. After this award, he beneficially owns 92,718 Class A shares, including the 3,908 unvested RSU shares that are subject to forfeiture until they vest.

Dolby Laboratories director Emily Rollins received an equity grant as part of her board compensation. On February 3, 2026, she was awarded 3,908 restricted stock units of Class A common stock at a price of $0 per share under Dolby’s 2020 Stock Plan.

Each unit represents one share that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholder meeting, as long as she continues serving on the board. After this grant, she beneficially owns 13,541 Class A shares, including the unvested units, which remain subject to forfeiture until they vest.

Dolby Laboratories director Peter C. Gotcher received an equity award of 3,908 restricted stock units (RSUs) of Class A Common Stock on February 3, 2026. The RSUs were granted at a price of $0 under Dolby’s 2020 Stock Plan.

Each RSU represents a right to receive one share of Class A Common Stock upon vesting. Vesting occurs on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if Gotcher continues serving on the board.

After this grant, Gotcher beneficially owns 44,641 shares of Class A Common Stock, including 3,908 shares underlying unvested RSUs that are subject to forfeiture until they vest.

Dolby Laboratories director Anjali Sud reported a grant of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026 at a price of $0. The award was made under Dolby’s 2020 Stock Plan.

Each RSU represents a contingent right to receive one Dolby Class A share that vests on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if she continues serving on the board. After this grant, she beneficially owns 16,079 Class A shares, including 3,908 unvested RSU-based shares that remain subject to forfeiture until they vest.

Dolby Laboratories director Tony A. Prophet received an equity award in the form of restricted stock units. On 02/03/2026, he was granted 3,908 restricted stock units of Class A common stock at a price of $0 per unit under the company’s 2020 Stock Plan.

Each unit converts into one share of Class A common stock upon vesting. Vesting will occur on the earlier of the first anniversary of the grant date or the day immediately before Dolby’s 2027 annual stockholders’ meeting, if he continues serving on the board. After this grant, he beneficially owns 13,015 Class A shares, including the unvested units, which are subject to forfeiture until they vest.

Dolby Laboratories director Avadis Tevanian reported an equity award and updated share holdings. On February 3, 2026, he received 3,908 restricted stock units (RSUs) of Class A common stock at $0 under Dolby’s 2020 Stock Plan.

Each RSU represents one share of Class A common stock and will vest on the earlier of the first anniversary of the grant date or immediately before Dolby’s 2027 annual shareholders’ meeting, contingent on his continued board service. Following this grant, he beneficially owns 3,908 shares directly through these RSUs and 62,670 shares indirectly held by the Avadis Tevanian Jr. and Nancy Tevanian Trust.

Dolby Laboratories senior executive John D. Couling reported a sale of company stock. On February 2, 2026, he sold 6,667 shares of Dolby Class A common stock at $64.885 per share. After this transaction, he beneficially owned 123,041 shares in total.

This total includes 55,114 shares of Class A common stock underlying restricted stock units. These restricted stock units are subject to forfeiture until they vest, meaning Couling’s ability to keep those shares depends on future vesting conditions being met.

Dolby Laboratories senior executive John Couling reported multiple equity awards and related share transactions in Class A common stock. On December 15, 2025, he received 25,633 restricted stock units under the 2020 Stock Plan, 12,816 performance-based restricted stock units, and an option to buy 56,440 shares at $66.62 per share.

The new PSU award has a three-year performance period from December 15, 2025 to December 12, 2028, with a potential payout from 0% to 200% of the 12,816-share target based on total shareholder return versus the S&P Mid Cap 400 Index and service-based vesting. A prior PSU grant with a 2022–2025 performance period vested at 64.65% of its 10,557-share target, resulting in 6,825 shares issued and 3,732 units cancelled. Shares worth 8,203 and 2,612 were withheld at prices of $67.54 and $66.62 to cover taxes, leaving 129,708 directly held Class A shares after the reported transactions, including 55,114 shares underlying unvested restricted stock units that are subject to forfeiture.

Dolby Laboratories executive Ryan Nicholson reported new equity awards and related share-withholding transactions. On December 15, 2025, he received an award of 9,032 restricted stock units under the company’s 2020 Stock Plan at a stated price of $0. One quarter of these units will vest on each anniversary of December 15, 2025, with each unit converting into one share of Class A common stock when it vests.

Also on December 15, 2025 and December 16, 2025, the company withheld 1,535 and 649 shares, respectively, at prices of $67.54 and $66.62 to cover taxes due upon vesting, in transactions exempt under Rule 16b-3. After these moves, Nicholson directly holds 36,956 Class A shares, including 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories, Inc. executive Todd Pendleton, SVP and Chief Marketing Officer, reported new equity awards and related share movements. On 12/15/2025 he received 18,848 restricted stock units, 9,424 performance-based restricted stock units, and options for 41,500 shares of Class A common stock at $66.62, all subject to multi-year vesting conditions.

On the same dates, 5,233 performance-based units from a prior award vested after a three-year performance period, while Dolby withheld 6,056 shares at $67.54 and 1,959 shares at $66.62 to cover taxes tied to vesting. After these transactions he beneficially owned 53,356 Class A shares, and shares held included 41,480 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories president and CEO Kevin Yeaman reported multiple equity transactions in December 2025. On December 15 he received 65,968 restricted stock units and a new performance-based restricted stock unit award covering 32,984 shares, plus an option to buy 145,252 shares of Class A common stock at $66.62 per share, all under Dolby’s 2020 Stock Plan. A prior performance-based award from 2022 vested at 64.65% of its 27,273-share target, delivering 17,633 shares while 9,640 units were cancelled, and Dolby withheld 27,180 and 6,855 shares to cover associated taxes. On December 16 and 17, a family trust for Yeaman sold several blocks of Dolby stock at weighted average prices including $66.6404 and $67.2351 per share under a Rule 10b5-1 trading plan adopted on February 28, 2025, and continues to hold Dolby shares on his behalf.

Dolby Laboratories senior vice president Shriram Revankar reported several equity compensation transactions. On December 15, 2025, he received 22,617 restricted stock units that vest in four annual installments starting December 15, 2025, and a new performance-based award covering 11,308 stock units tied to a three-year total shareholder return measure versus the S&P Mid Cap 400 Index.

He was also granted an employee stock option for 49,800 shares of Class A common stock at an exercise price of $66.62, vesting 25% after one year and monthly over the next 36 months until December 15, 2035. A prior performance-based award paid out at 64.65% of its 5,278-share target, so 3,412 units vested and 1,866 were cancelled, with shares withheld at $67.54 and $66.62 to cover taxes. After these transactions, he beneficially owns 86,218 Class A shares, including a large portion underlying unvested restricted stock units.

Dolby Laboratories executive Mark Andrew Sherman reported equity grants and share transactions in Class A common stock. On December 15, 2025 he received 25,633 restricted stock units that vest in four annual installments starting December 15, 2025, a performance-based restricted stock unit award for 12,816 target shares, and a stock option covering 56,440 shares at an exercise price of $66.62 per share.

Performance-based units originally granted in 2022 paid out at 64.65% of the 9,149-share target, resulting in 5,915 shares vesting and 3,234 PSUs being cancelled. To cover withholding taxes on vesting awards, the issuer withheld 9,252 and 2,530 shares at prices of $67.54 and $66.62. Sherman also sold 6,738, 2,371 and 2,491 shares on December 16 and 17, 2025 at weighted average prices of $66.5758, $67.1705 and $67.2637 under a Rule 10b5-1 trading plan adopted on February 28, 2025, and held 70,563 shares after these transactions, including 53,636 unvested restricted stock units.

Dolby Laboratories chief financial officer Robert Park reported new equity awards and related share movements in the company’s Class A common stock. On December 15, 2025 he received 23,371 restricted stock units under the 2020 Stock Plan, 11,685 performance-based restricted stock units tied to three-year total shareholder return, and 51,460 stock options exercisable at $66.62 per share.

A prior performance-based award with a target of 8,797 shares vested at 64.65% of target, resulting in 5,687 PSUs vesting and 3,110 being cancelled. Shares reported with transaction code F, totaling 6,473 and 2,285, were withheld to cover taxes on vesting. After these transactions, Park beneficially owns 86,385 Class A shares, including 48,874 shares underlying unvested restricted stock units that remain subject to future vesting.

Dolby Laboratories, Inc. executive John Couling, senior vice president of Entertainment, reported selling 7,273 shares of Class A common stock at $68.75 per share on 12/11/2025.

After this insider sale, he beneficially owned 108,065 Class A shares directly, including 48,526 shares underlying restricted stock units that are subject to forfeiture until they vest.

Dolby Laboratories, Inc. President and CEO Kevin Yeaman, who is also a director, reported option exercises and related share sales involving the company’s Class A common stock on 12/09/2025. Through the Kevin and Rachel Yeaman Family Trust, he exercised employee stock options for 10,615 shares at an exercise price of $64.6 and 23,752 shares at $45.5, then sold 28,168 shares at a weighted average price of $66.9919 and 6,199 shares at a weighted average price of $67.5052.

Following these transactions, the trust continued to hold Class A shares, and Yeaman also had 127,735 shares underlying restricted stock units that remain subject to vesting conditions, along with a small indirect holding reported as held by a son. The reported options were fully vested at exercise and now show no remaining derivative securities held through the trust.

Dolby Laboratories executive reports stock option exercise and sale. On 12/01/2025, EVP, General Counsel & Secretary Mark Andrew Sherman exercised an employee stock option for 4,500 shares of Dolby Class A common stock at an exercise price of $64.6 per share and acquired these shares.

On the same date, he sold 4,500 shares of Class A common stock at a weighted average price of $67.5635 per share in multiple transactions. Following these transactions, he beneficially owned 62,397 shares of Class A common stock, which include 45,470 shares underlying restricted stock units that remain subject to forfeiture until they vest.

Dolby Laboratories, Inc. (DLB) President and CEO Kevin Yeaman, who is also a director, reported multiple transactions in Class A common stock and related stock options. On November 24, 2025, a family trust exercised employee stock options for 25,000 shares at $45.50 and 11,699 shares at $64.60, increasing indirect holdings. That same day, the trust sold 36,699 shares at a weighted average price of $66.9066, with the shares sold in multiple transactions under a Rule 10b5-1 trading plan adopted on February 28, 2025.

On November 26, 2025, Mr. Yeaman gifted 16,348 shares of Class A common stock from the trust to a donor-advised fund for charitable purposes. Following the reported transactions, indirect holdings include 98,377 shares in the family trust and additional indirect ownership through restricted stock units and shares held by a son.

Dolby Laboratories, Inc. (DLB) reported an insider stock sale by a director. On 11/25/2025, a director sold 3,300 shares of Class A common stock in an open market transaction coded "S" at a price of $67.85 per share. After this sale, the director beneficially owned 9,107 shares of Class A common stock.

This remaining amount includes 3,140 shares underlying restricted stock units that are subject to forfeiture until they vest, meaning the director must meet vesting conditions before fully owning those shares.

Dolby Laboratories, Inc. insider activity: A company officer, identified as SVP of the Advanced Technology Group, reported selling 3,000 shares of Dolby Laboratories Class A common stock on 11/21/2025 at a price of $65.55 per share. After this transaction, the reporting person beneficially owns 67,435 shares of Class A common stock.

The remaining holdings include 47,766 shares underlying restricted stock units that may be forfeited if they do not vest, meaning a substantial portion of the reported ownership is still subject to vesting conditions over time.

Dolby Laboratories (DLB) senior vice president of entertainment reported a sale of Class A common stock. On 11/20/2025, the executive sold 6,164 shares of Dolby Class A common stock at a price of $66.12 per share. After this transaction, the executive beneficially owns 115,338 shares of Class A common stock. This total includes 48,526 shares underlying restricted stock units that may be forfeited if they do not vest, as well as 284 shares and 67 shares acquired through the company’s Employee Stock Purchase Plan on May 15, 2025 and November 17, 2025.

Dolby Laboratories (DLB) filed a Form 4 for CFO Robert Park. The filing reports 3,552 shares of Class A common stock withheld at $69.11 to cover taxes upon RSU vesting, a transaction exempt under Rule 16b‑3.

Following the withholding, Park beneficially owns 66,085 shares, including 38,186 shares underlying RSUs that remain subject to forfeiture until they vest. Holdings also include 350 shares acquired under the Employee Stock Purchase Plan on May 15, 2025.

Dolby Laboratories (DLB) reported insider activity by President & CEO and Director Kevin Yeaman. On 10/14/2025, he exercised an employee stock option for 25,000 Class A shares at $45.5 per share (code M), then sold 11,214 shares at a weighted average price of $68.5057 and 13,786 shares at a weighted average price of $69.173 (both code S), all held indirectly by a family trust. Following the reported transactions, 114,725 shares were beneficially owned indirectly by the trust. Holdings also include 127,735 RSUs that are subject to vesting.